Mounjaro® is a once‑weekly tirzepatide injection pen designed for the treatment of type 2 diabetes and weight management. Each multi‑dose KwikPen delivers 15 mg per dose, with a total of 4 doses included in one pen.
Key Benefits
- Provides significant reduction in HbA1c and improved glycaemic control
- Promotes weight loss and supports BMI reduction in overweight or diabetic patients
- Dual incretin action (GLP‑1 + GIP) helps reduce appetite & boosts insulin response
- Convenient once‑weekly subcutaneous injection in the abdomen, thigh, or upper arm
Dosage & Packaging
- Strength: 15 mg per 0.6 mL dose
- Content: 4 doses (2.4 mL total volume) per KwikPen
- Multi‑dose, single‑patient pen format
Indications & Safety
- Approved for adults with type 2 diabetes, obesity, or overweight with comorbidities
- Common side effects: nausea, diarrhea, constipation; serious but rare effects include pancreatitis, gallbladder issues, kidney injury
- Not for type 1 diabetes, diabetic ketoacidosis, or patients with personal/family history of medullary thyroid carcinomaor MEN 2
Storage Instructions
- Store refrigerated (2–8 °C / 36–46 °F)
- After first use, can be kept at room temperature per manufacturer recommendations
